Nexrutine inhibits cancer cell growth as a consequence of mitochondrial damage and mitophagy

Cellular Physiology and Biochemistry

Volumn 36, Issue 2, 2015, Pages 763-772

  Wu, Xiang ^a,b   Zhou, Shao Ming ^b   Ding, Yi Ling ^a   Gong, Ying Ping ^b   Zeng, Weiqi ^c   Cui, Yi ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Maternal and Child Health Hospital of Hunan Province   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Autophagy; Mitophagy; Nexrutine; p21; p27

Indexed keywords

ANTINEOPLASTIC AGENT; ATG7 PROTEIN; BECLIN 1; LACTATE DEHYDROGENASE; LACTIC ACID; NEXRUTINE; PHELLODENDRON AMURENSE EXTRACT; PROTEIN; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; UNCLASSIFIED DRUG; GLUCOSE; PLANT EXTRACT;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL DAMAGE; CELL GROWTH; CELL PROLIFERATION; DRUG MECHANISM; ENZYME ACTIVITY; GLUCOSE METABOLISM; HCT116 CELL LINE; HELA CELL LINE; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; MITOPHAGY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; U2OS CELL LINE; AUTOPHAGY; DRUG EFFECTS; HUMAN; MALE; METABOLISM; NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

PHELLODENDRON AMURENSE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; AUTOPHAGY; CELL LINE, TUMOR; CELL PROLIFERATION; GLUCOSE; HUMANS; MALE; MITOCHONDRIA; MITOCHONDRIAL DEGRADATION; NEOPLASMS; PLANT EXTRACTS;

EID: 84930245310     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000430136     Document Type: Article

References (41)

1. Seaver B, Smith JR: Inhibition of COX isoforms by nutraceuticals. J Herb Pharmacother 2004;4:11-18.
2. Ghosh R, Garcia GE, Crosby K, Inoue H, Thompson IM, Troyer DA, Kumar AP: Regulation of Cox-2 by cyclic AMP response element binding protein in prostate cancer: potential role for nexrutine. Neoplasia 2007;9:893-899.
3. Yount G, Qian Y, Moore D, Basila D, West J, Aldape K, Arvold N, Shalev N, Haas-Kogan D: Berberine sensitizes human glioma cells, but not normal glial cells, to ionizing radiation in vitro. J Exp Ther Oncol 2004;4:137-143.
4. Hou Q, Tang X, Liu H, Tang J, Yang Y, Jing X, Xiao Q, Wang W, Gou X, Wang Z: Berberine induces cell death in human hepatoma cells in vitro by downregulating CD147. Cancer Sci 2011;102:1287-1292.
5. Liu B, Wang G, Yang J, Pan X, Yang Z, Zang L: Berberine inhibits human hepatoma cell invasion without cytotoxicity in healthy hepatocytes. PLoS One 2011;6:e21416.
6. Garcia GE, Nicole A, Bhaskaran S, Gupta A, Kyprianou N, Kumar AP: Akt-and CREB-mediated prostate cancer cell proliferation inhibition by Nexrutine, a Phellodendron amurense extract. Neoplasia 2006;8:523-533.
7. Nohl H, Gille L, Staniek K: Intracellular generation of reactive oxygen species by mitochondria. Biochem Pharmacol 2005;69:719-723.
8. Green DR, Galluzzi L, Kroemer G: Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. Science 2011;333:1109-1112.
9. Luanpitpong S, Chanvorachote P, Nimmannit U, Leonard SS, Stehlik C, Wang L, Rojanasakul Y: Mitochondrial superoxide mediates doxorubicin-induced keratinocyte apoptosis through oxidative modification of ERK and Bcl-2 ubiquitination. Biochem Pharmacol 2012;83:1643-1654.
10. Das A, Gopalakrishnan B, Voss OH, Doseff AI, Villamena FA: Inhibition of ROS-induced apoptosis in endothelial cells by nitrone spin traps via induction of phase II enzymes and suppression of mitochondria-dependent pro-apoptotic signaling. Biochem Pharmacol 2012;84:486-497.
11. Sinha K, Das J, Pal PB, Sil PC: Oxidative stress: The mitochondria-dependentand mitochondria-independent pathways ofapoptosis. Arch Toxicol 2013;87:1157-1180.
12. Shi JM, Bai LL, Zhang DM, Yiu A, Yin ZQ, Han WL, Liu JS, Li Y, Fu DY, Ye WC: Saxifragifolin D induces the interplay between apoptosis and autophagy in breast cancer cells through ROS-dependent endoplasmic reticulum stress. Biochem Pharmacol 2013;85:913-926.
13. Caputo F, Vegliante R, Ghibelli L: Redox modulation of the DNA damage response. Biochem Pharmacol 2012;84:1292-1306.
14. Lizama-Manibusan B, McLaughlin B: Redox modification of proteins as essential mediators of CNS autophagy and mitophagy. FEBS Lett 2013;587:2291-2298.
15. Choi AM, Ryter SW, Levine B: Autophagy in human health and disease. N Engl J Med 2013;368:651-662.
16. TermanA, Brunk UT: Lipofuscin: mechanisms of formation and increase with age. APMIS 1998;106:265-276.
17. Lemasters JJ: Selective mitochondrial autophagy or mitophagy as a targeted defense against oxidative stress, mitochondrial dysfunction, and aging. Rejuvenation Res 2005;8:3-5.
18. PengX, Li W, Yuan L, Mehta RG, Kopelovich L, McCormick DL: Inhibition of proliferation and induction of autophagy by atorvastatin in PC3 prostate cancer cells correlate with downregulation of Bcl2 and upregulation ofmiR-182 and p21. PLoS One 2013;8:e70442.
19. Qi M, Zhou H, Fan S, Li Z, Yao G, Tashiro S, Onodera S, Xia M, Ikejima T: mTORinactivation by ROS-JNK-p53 pathway plays an essential role in Psedolaric acid B induced autophagy-dependent senescence in murine fibrosarcoma L929 cells. Eur J Pharmacol 2013;715:76-88.
20. Cho YY, Kim DJ, Lee HS, Jeong CH, Cho EJ, Kim MO, Byun S, Lee KY, Yao K, Carper A, Langfald A, Bode AM, Dong Z: Autophagy and cellular senescence mediated by Sox2 suppress malignancy of cancer cells. PLoS One2013;8:e57172.
21. Arndt CA, CristWM: Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 1999;341:342-352.
22. Cortes EP, Holland JF, Wang JJ, Sinks LF, Blom J, Senn H, Bank A, Glidewell O: Amputation and adriamycin in primary osteosarcoma. N Engl J Med 1974;291:998-1000.
23. Ochs JJ, FreemanAI, Douglass HO, Jr., Higby DS, Mindell ER, Sinks LF: cis-Dichlorodiammineplatinum (II) in advanced osteogenic sarcoma. Cancer Treat Rep 1978;62:239-245.
24. Jaffe N, Paed D, Farber S, Traggis D, Geiser C, Kim BS, Das L, Frauenberger G, Djerassi I, Cassady JR: Favorable response of metastatic osteogenic sarcoma to pulse high-dose methotrexate with citrovorum rescue and radiation therapy. Cancer 1973;31:1367-1373.
25. Harris MB, Cantor AB, Goorin AM, Shochat SJ, Ayala AG, Ferguson WS, Holbrook T, Link MP: Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previouslyuntreated: A Pediatric Oncology Group study. Med Pediatr Oncol 1995;24:87-92.
26. Miura M, Zhu H, Rotello R, Hartwieg EA, Yuan J: Induction of apoptosis in fibroblasts by IL-1 beta-converting enzyme, a mammalian homolog ofthe C. elegans cell death gene ced-3. Cell 1993;75:653-660.
27. Koppenol WH, Bounds PL, Dang CV: Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 2011;11:325-337.
28. Vander Heiden MG: Targeting cancer metabolism: A therapeutic window opens. Nat Rev Drug Discov 2011;10:671-684.
29. Kumar R, Das M, Ansari KM: Nexrutine(R) inhibits tumorigenesis in mouse skin and induces apoptotic cell death in human squamous carcinoma A431 and human melanoma A375 cells. Carcinogenesis 2012;33:1909-1918.
30. Yan G, Lanza-Jacoby S, Wang C: Nexrutine Inhibits Survival and Induces Gl Cell Cycle Arrest, Which Is Associated with Apoptosis or Autophagy Depending on the Breast Cancer Cell Line. Nutr Cancer 2014;66:506-516.
31. Draoui N, Feron O: Lactate shuttles at a glance: from physiological paradigms to anti-cancertreatments. Dis Model Mech 2011;4:727-732.
32. Kumar AP, Graham H, Robson C, Thompson IM, Ghosh R: Natural products: potential for developing Phellodendron amurense bark extract for prostate cancer management. Mini Rev Med Chem 2010;10:388-397.
33. Kumar AP, Bhaskaran S, Ganapathy M, Crosby K, Davis MD, Kochunov P, Schoolfield J, Yeh IT, Troyer DA, Ghosh R: Akt/cAMP-responsive element binding protein/cyclin Dl network: A novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by Nexrutine, a Phellodendron amurense bark extract. Clin Cancer Res 2007;13:2784-2794.
34. Ghosh R, Graham H, Rivas P, Tan XJ, Crosby K, Bhaskaran S, Schoolfield J, Banu J, Fernandes G, Yeh IT, Kumar AP: Phellodendron amurense bark extract prevents progression of prostate tumors in transgenic adenocarcinoma of mouse prostate: potential for prostate cancer management. Anticancer Res 2010;30:857-865.
35. Malhi H, Gores GJ, Lemasters JJ: Apoptosis and necrosis in the liver: A tale of two deaths? Hepatology 2006;43:S31-44.
36. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-825.
37. Strigari L, Mancuso M, Ubertini V, Soriani A, Giardullo P, Benassi M, DAlessio D, Leonardi S, Soddu S, Bossi G: Abscopal effect ofRadiationtherapy: Interplay between radiation dose and p53 Status. Int J Radiat Biol 2014;90:248-255.
38. Saha MN, Qiu L, Chang H: Targetingp53 by small molecules in hematological malignancies. J Hematol Oncol 2013;6:23.
39. Lam LT, Zhang H, Chyla B: Biomarkers of therapeutic response to BCL2 antagonists in cancer. Mol Diagn Ther2012;16:347-356.
40. Di Cresce C, Koropatnick J: Antisense treatment in human prostate cancer and melanoma. Curr Cancer DrugTargets 2010;10:555-565.
41. Buckman JF, Hernandez H, Kress GJ, Votyakova TV, Pal S, Reynolds IJ: Mito-Tracker labeling in primary neuronal and astrocytic cultures: influence of mitochondrial membrane potential and oxidants. J Neurosci Meth2001;104:165-176.